Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects With Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication

NCT02004392 is registered in ClinicalTrials.gov with FORUM Pharmaceuticals Inc as lead sponsor.

NCT NCT02004392
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02004392 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects With Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication
Lead sponsor
FORUM Pharmaceuticals Inc
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2014
Completion date
August 31, 2017
Enrollment
348 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, dementia